Who are etanercept (EnbrelTM)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): 1=Etanercept.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/etanercept-enbreltm.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

etanercept (EnbrelTM) — Competitive Intelligence Brief

etanercept (EnbrelTM) (etanercept (EnbrelTM)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF receptor antagonist (TNF inhibitor). Area: Immunology.

marketed TNF receptor antagonist (TNF inhibitor) TNF-α and TNF-β (tumor necrosis factor) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

etanercept (EnbrelTM) (etanercept (EnbrelTM)) — Wyeth is now a wholly owned subsidiary of Pfizer. Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving immune-mediated diseases.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
etanercept (EnbrelTM) TARGET	etanercept (EnbrelTM)	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	TNF receptor antagonist (TNF inhibitor)	TNF-α and TNF-β (tumor necrosis factor)
1=Etanercept	1=Etanercept	Amgen	phase 3	TNF receptor antagonist (TNF inhibitor)	TNF-α (Tumor Necrosis Factor-alpha) and TNF-β

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF receptor antagonist (TNF inhibitor) class)

Amgen · 1 drug in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). etanercept (EnbrelTM) — Competitive Intelligence Brief. https://druglandscape.com/ci/etanercept-enbreltm. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab